

## IN THE CLAIMS

Claim 1 (currently amended):        A method of treating or ameliorating a hyperproliferative disease selected from the group consisting of breast cancer, prostate cancer, colon cancer, lung cancer, and head and neck cancer in a subject comprising administering to said subject a therapeutically effective dose of a gossypol compound and one or more second agent(s) selected from an anticancer agent and/or radiation, wherein said gossypol compound is selected from the group consisting of (±)-ethyl gossypol, (-)-ethyl gossypol, and (+)-ethyl gossypol, ~~(±)-apogossypol, (-)-apogossypol, (+)-apogossypol, (±)-apogossypol acetic acid, (-)-apogossypol acetic acid, (+)-apogossypol acetic acid, (±)-ethyl apogossypol, (-)-ethyl apogossypol, and (+)-ethyl apogossypol.~~

Claim 2 (previously presented):        The method of claim 1, wherein said gossypol compound is provided in a dose that sensitizes said subject to treatment by said one or more second agent(s).

Claims 3-26 (canceled)

Claim 27 (original):    The method of claim 1, wherein said hyperproliferative disease is associated with overexpression of a Bcl-2 family member protein.

Claim 28 (original): The method of claim 27, wherein said Bcl-2 family protein is Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, A1/BFL-1, BOO-DIVA, Bcl-w, Bcl-6, Bcl-8, or Bcl-y.

Claim 29 (original): The method of claim 1, wherein said subject is a human.

Claims 30-31 (canceled)

Claim 32 (previously presented): The method of claim 1, wherein said cancer is metastatic.

Claim 33 (previously presented): The method of claim 1, wherein said cancer is a tumor and the treatment or amelioration results in regression of the tumor.

Claim 34 (previously presented): The method of claim 1, wherein said cancer is resistant to anticancer agent and/or radiation therapy.

Claim 35 (previously presented): The method of claim 34, wherein said gossypol compound sensitizes said cancer to said anticancer agent and/or radiation therapy.

Claim 36 (previously presented): The method of claim 1, wherein said gossypol compound and said anticancer agent and/or radiation are administered simultaneously.

Claim 37 (previously presented): The method of claim 1, wherein said gossypol compound and said anticancer agent and/or radiation are administered sequentially.

Claim 38 (previously presented): The method of claim 37, wherein said gossypol compound is administered prior to said anticancer agent and/or radiation.

Claim 39 (previously presented): The method of claim 37, wherein said gossypol compound is administered after said anticancer agent and/or radiation.

Claim 40 (previously presented): The method of claim 1, wherein said gossypol compound and said anticancer agent and/or radiation are administered with different periodicities, different durations, different concentrations, and/or different administration routes.

Claim 41 (previously presented): The method of claim 1, wherein said anticancer agent and/or radiation is selected from docetaxel, paclitaxel, cisplatin, carboplatin, radiation therapy, and combinations thereof.

Claim 42 (canceled)

Claim 43 (previously presented): The method of claim 1, wherein said gossypol compound and said anticancer agent and/or radiation have a synergistic therapeutic effect.

Claim 44 (canceled)

Claim 45 (original): The method of claim 1, wherein said second agent is radiation.

Claim 46 (currently amended): A pharmaceutical composition comprising a gossypol compound and one or more anticancer agents, wherein said gossypol compound is selected from the group consisting of (±)-ethyl gossypol, (-)-ethyl gossypol, and (+)-ethyl gossypol, ~~(±) apogossypol, (-) apogossypol, (+) apogossypol, (±) apogossypol acetic acid, (-) apogossypol acetic acid, (+) apogossypol acetic acid, (±) ethyl apogossypol, (-) ethyl apogossypol, and (+) ethyl apogossypol.~~

Claim 47 (previously presented): The pharmaceutical composition of claim 46, wherein said anticancer agent is selected from docetaxel, paclitaxel, cisplatin, carboplatin, and combinations thereof.

Claim 48 (canceled)

Claim 49 (currently amended):       A kit comprising a gossypol compound, one or more anticancer agents, and instructions for administering said gossypol compound and said anticancer agents to a subject, wherein said gossypol compound is selected from the group consisting of (±)-ethyl gossypol, (-)-ethyl gossypol, (+)-ethyl gossypol, and (+)-ethyl gossypol, ~~(±)-apogossypol, (-)-apogossypol, (+)-apogossypol, (±)-apogossypol acetic acid, (-)-apogossypol acetic acid, (+)-apogossypol acetic acid, (±)-ethyl apogossypol, (-)-ethyl apogossypol, and (+)-ethyl apogossypol.~~

Claim 50 (previously presented):    The kit of claim 49, wherein said anticancer agent is selected from docetaxel, paclitaxel, cisplatin, carboplatin, and combinations thereof.

Claim 51 (canceled)

Claim 52 (previously presented):    A method of treating or ameliorating breast cancer or prostate cancer in a subject comprising administering to said subject a therapeutically effective dose of (-)-gossypol and one or more second agent(s) selected from docetaxel, paclitaxel, and/or radiation, wherein the combination of (-)-gossypol and (a) second agent(s) produces a synergistic effect with respect to one or more of tumor shrinkage, tumor loss, time to tumor progression, or survival.

Claim 53 (previously presented): The method of claim 52, wherein said (-)-gossypol is provided in a dose that sensitizes said subject to treatment by said one or more second agent(s).

Claims 54-77 (canceled)

Claim 78 (previously presented): The method of claim 52, wherein said cancer is associated with overexpression of a Bcl-2 family member protein.

Claim 79 (previously presented): The method of claim 78, wherein said Bcl-2 family protein is Bcl-2, Bcl-X<sub>L</sub>, Mcl-1, A1/BFL-1, BOO-DIVA, Bcl-w, Bcl-6, Bcl-8, or Bcl-y.

Claim 80 (previously presented): The method of claim 52, wherein said subject is a human.

Claims 81-83 (canceled)

Claim 84 (previously presented): The method of claim 52, wherein said cancer is metastatic.

Claim 85 (previously presented): The method of claim 52, wherein said cancer is a tumor and the treatment or amelioration results in regression of the tumor.

Claim 86 (previously presented): The method of claim 85, wherein the treatment or amelioration results in complete regression of the tumor.

Claim 87 (previously presented): The method of claim 52, wherein said cancer is resistant to anticancer agent or radiation therapy.

Claim 88 (previously presented): The method of claim 87, wherein said (-)-gossypol sensitizes said cancer to said anticancer agent(s) and/or radiation therapy.

Claim 89 (previously presented): The method of claim 52, wherein said (-)-gossypol and said one or more second agent(s) are administered simultaneously.

Claim 90 (previously presented): The method of claim 52, wherein said (-)-gossypol and said one or more second agent(s) are administered sequentially.

Claim 91 (previously presented): The method of claim 90, wherein said (-)-gossypol is administered prior to said one or more second agent(s).

Claim 92 (previously presented):     The method of claim 90, wherein said (-)-gossypol is administered after said one or more second agent(s).

Claim 93 (previously presented):     The method of claim 52, wherein said (-)-gossypol and said one or more second agent(s) are administered with different periodicities, different durations, different concentrations, and/or different administration routes.

Claims 94-95 (canceled)

Claim 96 (previously presented):     The method of claim 52, wherein said second agent is radiation.

Claim 97 (canceled)